Bedrijfsoverzicht
Delcath Systems, Inc. is an interventional oncology enterprise dedicated to the treatment of primary and metastatic liver cancers within the United States and European markets. The company operates within the broader Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on tangible assets and specialized equipment for clinical procedures. At a market capitalization of $348.85M, the firm manages an annual revenue of $85.23M and employs a workforce of 156 individuals. These valuation and revenue figures indicate a mid-cap positioning that suggests the company is established enough to generate significant sales but remains in a phase where capital allocation towards growth and operational scaling is likely prioritized over maximizing immediate shareholder yield. The relatively small employee count relative to the market capitalization highlights a lean operational structure typical of specialized medical device manufacturers.
Financiële gezondheid
The company reported a revenue of $85.23M over the trailing twelve months, generating a net income of $2.70M and an EBITDA of $898,000. The substantial disparity between the $85.23M in revenue and the $2.70M in net income reveals a cost structure where operating expenses and tax obligations consume a significant portion of gross receipts, resulting in a net profit margin of only 3.2%. Despite the lower net income, the company maintains a robust free cash flow of $20.29M, which indicates strong financial flexibility and the ability to fund operations, repay debt, or invest in research and development without relying on external financing. The gross margin stands at 86.2%, reflecting the high value of the medical devices sold relative to their cost of goods sold. However, the operating margin is negative at -10.5%, signaling that fixed overhead costs currently exceed the operating profit generated from core business activities. The profit margin of 3.2% confirms that while the company is profitable on a bottom-line basis, it operates with thin profitability relative to its top-line sales. On the balance sheet, Delcath holds $91.04M in cash against a minimal debt load of $936,000, resulting in a debt-to-equity ratio of 0.84 which suggests a moderately leveraged but predominantly cash-funded position. The current ratio of 10.92 is exceptionally high, indicating that the company possesses more than ten times the current assets necessary to cover its short-term liabilities, pointing to superior short-term liquidity. Return on Equity (ROE) is recorded at 3.0% and Return on Assets (ROA) at 0.4%, metrics that reveal that management effectiveness in generating returns on investor capital and total assets is currently limited, likely due to the heavy investment phase or high operating leverage inherent in the medical device sector.
Waarderingsbeoordeling
The stock carries a trailing P/E ratio of 143.43 and a forward P/E of -51.22. The divergence between these two metrics, specifically the negative forward P/E, implies that analysts do not expect positive earnings in the near future, likely due to anticipated increases in operating expenses that will temporarily suppress profitability. The price-to-book ratio is 3.13, indicating that the market values the company at a significant premium over its net book value, which often reflects the value of intangible assets or future growth potential rather than current asset backing. Alternative valuation metrics such as the price-to-sales ratio of 4.09 and the EV/EBITDA of 288.14 suggest that the stock is priced aggressively relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. The 52-week high is $18.23 and the 52-week low is $8.12, providing a trading range that contextualizes current price movements. Without a specific current share price provided in the facts, the valuation range can be assessed as having a wide dispersion of $10.11 between the high and low, illustrating the stock's sensitivity to market conditions. The beta value of 0.43 indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting it may act as a defensive position within a diversified portfolio despite its high valuation multiples.
Growth & Income
Revenue growth year-over-year is recorded at 37.3%, demonstrating a robust expansion in top-line sales driven by product adoption or market penetration. Earnings growth is listed as N/A, which implies that while sales are expanding rapidly, the conversion of those sales into earnings has not yet stabilized or is currently volatile. The lack of a defined earnings growth rate suggests that earnings are currently lagging behind the impressive revenue trajectory, a common pattern for companies scaling their operations and investing heavily in production or marketing capabilities. Regarding income, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This policy indicates that the firm chooses to reinvest its earnings directly back into the business to fuel growth initiatives rather than distributing cash to shareholders. The overall growth and income profile is characterized by high sales acceleration and zero dividend distribution, positioning the company as a pure growth play for investors seeking capital appreciation rather than income generation.